Chromocell Therapeutics Discounted Cash Flow

Chromocell Therapeutics (CHRO) currently reports a DCF fair value of $-0.3. Use the charts on this page to explore Chromocell Therapeutics's DCF fair value history and peer comparisons.

Chromocell Therapeutics's discounted cash flow (DCF) fair value estimate is $-0.3, about 122.2% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $-0.3, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.